X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs LUPIN LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB LUPIN LTD DR. REDDYS LAB/
LUPIN LTD
 
P/E (TTM) x 34.3 22.6 151.7% View Chart
P/BV x 3.4 3.1 109.8% View Chart
Dividend Yield % 0.8 0.8 98.2%  

Financials

 DR. REDDYS LAB   LUPIN LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
LUPIN LTD
Mar-17
DR. REDDYS LAB/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3,3971,750 194.1%   
Low Rs2,5601,384 185.0%   
Sales per share (Unadj.) Rs856.5387.4 221.1%  
Earnings per share (Unadj.) Rs78.056.6 137.7%  
Cash flow per share (Unadj.) Rs139.976.8 182.1%  
Dividends per share (Unadj.) Rs20.007.50 266.7%  
Dividend yield (eoy) %0.70.5 140.3%  
Book value per share (Unadj.) Rs739.8298.9 247.5%  
Shares outstanding (eoy) m165.74451.58 36.7%   
Bonus/Rights/Conversions BBESOPS-  
Price / Sales ratio x3.54.0 86.0%   
Avg P/E ratio x38.227.7 138.1%  
P/CF ratio (eoy) x21.320.4 104.4%  
Price / Book Value ratio x4.05.2 76.8%  
Dividend payout %25.713.2 193.7%   
Avg Mkt Cap Rs m493,632707,513 69.8%   
No. of employees `00022.716.8 135.1%   
Total wages/salary Rs m31,06828,495 109.0%   
Avg. sales/employee Rs Th6,259.010,418.3 60.1%   
Avg. wages/employee Rs Th1,369.81,697.0 80.7%   
Avg. net profit/employee Rs Th569.71,523.0 37.4%   
INCOME DATA
Net Sales Rs m141,961174,943 81.1%  
Other income Rs m1,7151,065 161.0%   
Total revenues Rs m143,676176,008 81.6%   
Gross profit Rs m24,72244,931 55.0%  
Depreciation Rs m10,2669,122 112.5%   
Interest Rs m6341,525 41.6%   
Profit before tax Rs m15,53735,349 44.0%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m34983 423.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9659,785 30.3%   
Profit after tax Rs m12,92125,575 50.5%  
Gross profit margin %17.425.7 67.8%  
Effective tax rate %19.127.7 68.9%   
Net profit margin %9.114.6 62.3%  
BALANCE SHEET DATA
Current assets Rs m96,837119,542 81.0%   
Current liabilities Rs m84,19961,206 137.6%   
Net working cap to sales %8.933.3 26.7%  
Current ratio x1.22.0 58.9%  
Inventory Days Days7376 96.5%  
Debtors Days Days9890 108.7%  
Net fixed assets Rs m102,552131,660 77.9%   
Share capital Rs m829903 91.8%   
"Free" reserves Rs m121,792134,073 90.8%   
Net worth Rs m122,621134,976 90.8%   
Long term debt Rs m5,44956,478 9.6%   
Total assets Rs m218,165266,073 82.0%  
Interest coverage x25.524.2 105.5%   
Debt to equity ratio x00.4 10.6%  
Sales to assets ratio x0.70.7 99.0%   
Return on assets %6.210.2 61.0%  
Return on equity %10.518.9 55.6%  
Return on capital %12.919.3 67.0%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67081,885 99.7%   
Fx outflow Rs m26,35521,506 122.5%   
Net fx Rs m55,31560,378 91.6%   
CASH FLOW
From Operations Rs m21,44441,148 52.1%  
From Investments Rs m-18,404-25,287 72.8%  
From Financial Activity Rs m-3,6924,332 -85.2%  
Net Cashflow Rs m-1,14420,193 -5.7%  

Share Holding

Indian Promoters % 25.5 46.6 54.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 31.9 110.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.1 151.5%  
Shareholders   75,885 98,259 77.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 17, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - STERLING BIOTECH COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS